title: Ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroid & adenomyosis: A single center experience from the Republic of Korea.
abstract: OBJECTIVE
  This study aimed to assess the therapeutic outcomes of patients with uterine fibroid or adenomyosis treated by ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation at Incheon Christian Hospital, Korea.
  
  
  METHODS
  This study included 618 patients, of which 272 suffered from uterine fibroid and 346 suffered from adenomyosis. Treatment was administrated using the Model Haifu JC Focused Ultrasound Tumor Therapeutic System (Chongqing Haifu Technology, Chongqing, China) under real-time ultrasound guidance. A follow-up was conducted on volume change as well as on symptom improvement using the Symptom Severity Score (SSS) and Uterine Fibroid Symptom and Quality of Life (UFS-QOL) after treatment.
  
  
  RESULTS
  The uterine fibroid volume reduction rates (%) were 58.08%, 66.18%, and 77.59% at 3, 6, and 12 months after treatment, respectively. The SSS reduction rates (%) were 55.58%, 52.76%, and 50.39% by 3, 6, and 12 months, respectively. The UFS-QOL score increasing rates (%) were 42.66%, 43.50%, and 43.45% by 3, 6, and 12 months, respectively. The uterine volume reduction rates (%) for adenomyosis were 43.99%, 47.01%, and 53.98% by 3, 6, and 12 months, respectively. The SSS reduction rates (%) for adenomyosis were 55.61%, 52.38%, and 57.98% by 3, 6, and 12 months, respectively. The UFS-QOL score increasing rates (%) for adenomyosis UFS-QOL score were 80.06%, 69.39%, and 85.07% by 3, 6, and 12 months, respectively.
  
  
  CONCLUSIONS
  We conclude that USgHIFU treatment for uterine fibroid and adenomyosis is an effective non-invasive therapy via the assessment of fibroid volume reduction, symptom improvement, UFS-QOL score increase, and acceptable level of side effects. Although preliminary experience of HIFU is encouraging, well-designed prospective trials and more clinical experiences are needed to ascertain the efficacy and safety of this new treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Incheon Christian Hospital, Incheon, Republic of Korea.
authors.forename: Jae-Seong
authors.initials: JS
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
authors.forename: Gi-Youn
authors.initials: GY
authors.lastname: Hong
authors.affiliation: Department of Obstetrics and Gynecology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
authors.forename: Byung-Joon
authors.initials: BJ
authors.lastname: Park
authors.affiliation: Department of Obstetrics and Gynecology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address: tekim@catholic.ac.kr.
authors.forename: Tea-Eung
authors.initials: TE
authors.lastname: Kim
mesh_terms: D062788:Adenomyosis / Q000473:pathology / Q000601:surgery*; D000328:Adult; D005260:Female; D057086:High-Intensity Focused Ultrasound Ablation / Q000009:adverse effects; D006801:Humans; D007889:Leiomyoma / Q000473:pathology / Q000601:surgery*; D008875:Middle Aged; D009929:Organ Size; D011788:Quality of Life; D056910:Republic of Korea; D012189:Retrospective Studies; D016896:Treatment Outcome; D014599:Uterus / Q000473:pathology / Q000601:surgery; D055815:Young Adult
keywords: Adenomyosis; HIFU; Uterine fibroid